Education
About Us
Working with TipRanks
Follow Us
Crispr Therapeutics AG (CRSP)
NASDAQ:CRSP
CRSP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$36.52 - $73.09
Previous CloseN/A
Volume437.82K
Average Volume (3M)2.30M
Market Cap
$3.54B
Enterprise Value$2.30B
Total Cash (Recent Filing)$298.26M
Total Debt (Recent Filing)$223.69M
Price to Earnings (P/E)―
Beta2.08
Next Earnings
May 12, 2025EPS Estimate
-1.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.36
Shares Outstanding85,774,475
10 Day Avg. Volume1,589,478
30 Day Avg. Volume2,297,955
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)94.75
Price to Cash Flow (P/CF)-17.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.65
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit61.54
Enterprise Value/Ebitda-5.13
Forecast
1Y Price Target
$71.58Price Target Upside73.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20
---
Bulls Say, Bears Say
Bulls Say
Financial FoundationThe in-house manufacturing capability and $1.9 billion of cash provide a strong financial and operational foundation for CRSP.
Market ApprovalsThe Casgevy launch is expected to accelerate due to approvals in the UAE and anticipated approvals in Kuwait and Qatar.
Pipeline Updates2025 will feature key updates across the breadth of CRISPR Therapeutics' pipeline in large indications, covering IO, I&I, in-vivo editing, and diabetes.
Bears Say
Launch PerformanceCasgevy launch was slower than Street expectations, causing a reduction in the price target.
Regimen ChallengesUptake has been slow due to the intense commitment of the myeloablation conditioning regimen and the permanent nature and novelty of gene editing.
---
Ownership Overview
1.66% Insiders
17.95% Mutual Funds
46.34% Other Institutional Investors
16.51% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CRSP FAQ
What was Crispr Therapeutics AG’s price range in the past 12 months?
Crispr Therapeutics AG lowest stock price was $36.52 and its highest was $73.09 in the past 12 months.
What is Crispr Therapeutics AG’s market cap?
Crispr Therapeutics AG’s market cap is $3.54B.
When is Crispr Therapeutics AG’s upcoming earnings report date?
Crispr Therapeutics AG’s upcoming earnings report date is May 12, 2025 which is in 49 days.
How were Crispr Therapeutics AG’s earnings last quarter?
Crispr Therapeutics AG released its earnings results on Feb 11, 2025. The company reported -$0.44 earnings per share for the quarter, beating the consensus estimate of -$1.201 by $0.761.
Is Crispr Therapeutics AG overvalued?
According to Wall Street analysts Crispr Therapeutics AG’s price is currently Undervalued.
Does Crispr Therapeutics AG pay dividends?
Crispr Therapeutics AG does not currently pay dividends.
What is Crispr Therapeutics AG’s EPS estimate?
Crispr Therapeutics AG’s EPS estimate is -1.23.
How many shares outstanding does Crispr Therapeutics AG have?
Crispr Therapeutics AG has 85,774,475 shares outstanding.
What happened to Crispr Therapeutics AG’s price movement after its last earnings report?
Crispr Therapeutics AG reported an EPS of -$0.44 in its last earnings report, beating expectations of -$1.201. Following the earnings report the stock price went up 9.288%.
Which hedge fund is a major shareholder of Crispr Therapeutics AG?
Currently, no hedge funds are holding shares in CRSP
---
Crispr Therapeutics AG Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$71.58 (73.65% Upside)
$71.58 (73.65% Upside)
Blogger Sentiment
Bullish
CRSP Sentiment 94%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 2.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $313.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 4.5%
Last 30 Days ▼ 4.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.67%
12-Months-Change
Fundamentals
Return on Equity
-19.20%
Trailing 12-Months
Asset Growth
0.56%
Trailing 12-Months
Company Description
Crispr Therapeutics AG
Crispr Therapeutics AG (CRSP) is a leading biotechnology company focused on developing transformative gene-based medicines using its proprietary CRISPR/Cas9 platform. The company operates primarily in the healthcare sector, with a core focus on gene editing technologies. Crispr Therapeutics is dedicated to creating therapies for serious diseases such as hemoglobinopathies, oncology, regenerative medicine, and rare diseases.
---
CRSP Stock 12 Month Forecast
Average Price Target
$71.58
▲(73.65% Upside)
Technical Analysis
Sangamo Biosciences
―
Editas Medicine
―
Intellia Therapeutics
―
Beam Therapeutics
―
Verve Therapeutics
―
Best Analysts Covering CRSP
1 Year
1 Year Success Rate
17/41 ratings generated profit
1 Year Average Return
+17.54%
reiterated a buy rating last month
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 41.46% of your transactions generating a profit, with an average return of +17.54% per trade.
---